Viad - VVI Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Viad in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VVI shares.
View VVI analyst ratings or view top-rated stocks.

3 equities research analysts have issued 12 month price targets for Viad's stock. Their VVI share price forecasts range from $42.00 to $51.00. On average, they anticipate the company's stock price to reach $45.00 in the next year. This suggests a possible upside of 38.1% from the stock's current price.
View analysts price targets for VVI or view top-rated stocks among Wall Street analysts.

Viad's stock was trading at $42.79 at the beginning of the year. Since then, VVI stock has decreased by 23.9% and is now trading at $32.58.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our VVI earnings forecast.

Viad Corp (NYSE:VVI) posted its earnings results on Thursday, November, 4th. The business services provider reported $0.58 EPS for the quarter, missing analysts' consensus estimates of $1.75 by $1.17. The business services provider had revenue of $233.60 million for the quarter, compared to the consensus estimate of $150.27 million. Viad had a negative net margin of 1.82% and a negative trailing twelve-month return on equity of 10.53%. During the same period last year, the business earned ($0.81) earnings per share.

5 employees have rated Viad Chief Executive Officer Steve W. Moster on Glassdoor.com. Steve W. Moster has an approval rating of 80% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Viad investors own include Pfizer (PFE), AbbVie (ABBV), Verizon Communications (VZ), Dynavax Technologies (DVAX), Enbridge (ENB), Procter & Gamble (PG), QUALCOMM (QCOM), Trevena (TRVN), Universal Technical Institute (UTI) and VBI Vaccines (VBIV).

Viad trades on the New York Stock Exchange (NYSE) under the ticker symbol "VVI."

Viad's stock is owned by many different institutional and retail investors. Top institutional investors include Victory Capital Management Inc. (11.47%), Allspring Global Investments Holdings LLC (7.13%), River Road Asset Management LLC (4.36%), State Street Corp (3.39%), Aristotle Capital Boston LLC (3.36%) and Penn Capital Management Company LLC (1.78%). Insiders that own company stock include Andrew B Benett, David W Barry, Ellen M Ingersoll, Jeffrey A Stelmach, Joshua Schechter and Steven W Moster.
View institutional ownership trends.

Shares of VVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VVI stock can currently be purchased for approximately $32.58.

Viad (NYSE:VVI) has a market capitalization of $671.83 million and generates $507.34 million in revenue each year. The business services provider earns $-92,650,000.00 in net income (profit) each year or ($1.66) on an earnings per share basis.

The company employs 3,512 workers across the globe.

Viad's mailing address is 1850 NORTH CENTRAL AVENUE SUITE 1900, PHOENIX AZ, 85004. The official website for the company is www.viad.com. The business services provider can be reached via phone at (602) 207-1000, via email at investorrelations@viad.com, or via fax at 602-207-5834.